Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chi Don Biotechnology Co. Ltd. is currently engaged in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This matter is being reviewed by 1 distinct examiner, BOECKELMAN, JACOB A. The prosecution is localized within 1 distinct art unit, reflecting a focused approach to its intellectual property. This concentration suggests that the company's current legal efforts are directed toward a specific technical niche within its field.
The busiest examiner, BOECKELMAN, JACOB A, is assigned 1 pending office action, which represents the total active volume for the company. Because there is only 1 distinct examiner and 1 distinct art unit, the company's current prosecution efforts are entirely centralized. This eliminates the need for managing multiple examiner relationships or navigating different art unit norms, allowing for a highly efficient response strategy.
The 1 pending office action serves as the primary focus for the company's current USPTO strategy. With 1 distinct examiner involved, the company can apply a targeted approach to its patent goals. This structure provides a clear and direct path for the outstanding matter currently under review, as the 1 distinct art unit classification ensures that the technical arguments remain within a unified administrative framework.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725674 | CHINESE HERBAL MEDICINE EXTRACT, METHOD FOR PREPARING THE SAME, AND USE OF THE SAME | BOECKELMAN, JACOB A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725674 | CHINESE HERBAL MEDICINE EXTRACT, METHOD FOR PREPARING THE SAME, AND USE OF THE SAME | BOECKELMAN, JACOB A | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725674 | CHINESE HERBAL MEDICINE EXTRACT, METHOD FOR PREPARING THE SAME, AND USE OF THE SAME | BOECKELMAN, JACOB A | 1655 | §101§103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial